Shared on 17 Aug 25
Fair value Increased 5.42%700 New Beds And Digital Health Will Reshape Healthcare Delivery
The upward revision in Apollo Hospitals Enterprise's price target reflects improved profitability, as evidenced by a higher net profit margin and a lower future P/E, resulting in a new consensus fair value of ₹8,587. What's in the News Board meeting scheduled to consider unaudited Q1 FY26 financial results and potential acquisition of Parkway Healthcare's 50% stake in Gleneagles PET-CT Private Limited.
Shared on 01 May 25
Fair value Increased 1.97%700 New Beds And Digital Health Will Reshape Healthcare Delivery
Shared on 23 Apr 25
Fair value Increased 0.086%Expanding Into High-End Specialties And Emerging Markets Will Strengthen Future Prospects
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 17 Apr 25
Fair value Decreased 0.049%Expanding Into High-End Specialties And Emerging Markets Will Strengthen Future Prospects
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 09 Apr 25
Fair value Decreased 0.48%Expanding Into High-End Specialties And Emerging Markets Will Strengthen Future Prospects
AnalystConsensusTarget has decreased revenue growth from 16.3% to 14.5% and increased profit margin from 9.0% to 10.3%.
Shared on 02 Apr 25
Fair value Increased 3.09%Expanding Into High-End Specialties And Emerging Markets Will Strengthen Future Prospects
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 26 Mar 25
Expanding Into High-End Specialties And Emerging Markets Will Strengthen Future Prospects
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 19 Mar 25
Fair value Decreased 0.17%Expanding Into High-End Specialties And Emerging Markets Will Strengthen Future Prospects
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 12 Mar 25
Fair value Decreased 3.89%Expanding Into High-End Specialties And Emerging Markets Will Strengthen Future Prospects
AnalystConsensusTarget has increased shares outstanding growth rate from 0.0% to 0.0%.